NASDAQ:FBIO - Fortress Biotech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.60
  • Forecasted Upside: 208.14 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$3.44
▲ +0.1 (2.99%)

This chart shows the closing price for FBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fortress Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FBIO

Analyst Price Target is $10.60
▲ +208.14% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Fortress Biotech in the last 3 months. The average price target is $10.60, with a high forecast of $21.00 and a low forecast of $5.00. The average price target represents a 208.14% upside from the last price of $3.44.

This chart shows the closing price for FBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Fortress Biotech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/17/2021B. RileyLower Price TargetAccumulate ➝ Buy$9.00 ➝ $8.00Medium
4/20/2021Roth CapitalBoost Price TargetBuy$4.50 ➝ $5.00Medium
4/5/2021B. RileyReiterated RatingBuy$8.00 ➝ $9.00High
4/1/2021Cantor FitzgeraldReiterated RatingOverweightN/A
2/26/2021HC WainwrightReiterated RatingBuy$10.00Low
2/17/2021Dawson JamesBoost Price TargetBuy$16.00 ➝ $21.00Low
12/17/2020B. RileyReiterated RatingBuyHigh
10/13/2020Roth CapitalLower Price TargetBuy$5.00 ➝ $4.75High
10/12/2020HC WainwrightLower Price TargetBuy$11.00 ➝ $10.00High
10/2/2020BenchmarkInitiated CoverageBuy$9.00 ➝ $9.00Medium
8/21/2020B. RileyBoost Price Target$6.00 ➝ $8.00Low
8/12/2020B. RileyReiterated RatingBuy$6.00Medium
5/18/2020B. RileyReiterated RatingBuy$6.00Low
5/8/2020HC WainwrightReiterated RatingBuy$11.00High
3/17/2020Cantor FitzgeraldReiterated RatingOverweightHigh
3/13/2020B. RileyLower Price TargetBuy$9.00 ➝ $6.00Low
2/12/2020Cantor FitzgeraldInitiated CoverageOverweight$6.00High
12/18/2019B. RileyInitiated CoverageBuy$9.00High
8/26/2019Dawson JamesInitiated CoverageBuy$19.00High
7/1/2019Roth CapitalInitiated CoverageBuy$4.00Low
5/13/2019HC WainwrightReiterated RatingBuy$11.00High
2/20/2019HC WainwrightReiterated RatingBuy$11.00Medium
2/14/2019HC WainwrightSet Price TargetBuy$11.00High
8/10/2018HC WainwrightSet Price TargetBuy$11.00N/A
5/21/2018JMP SecuritiesSet Price TargetBuy$11.00High
5/21/2018HC WainwrightSet Price TargetBuy$11.00High
5/11/2018HC WainwrightSet Price TargetBuy$11.00High
3/27/2018HC WainwrightSet Price TargetBuy$11.00Low
3/16/2018HC WainwrightReiterated RatingBuy$11.00Low
2/28/2018B. RileyInitiated CoverageBuy ➝ Buy$10.00High
1/2/2018HC WainwrightSet Price TargetBuy$11.00Low
12/12/2017HC WainwrightSet Price TargetBuy$11.00High
12/5/2017HC WainwrightReiterated RatingBuy$11.00High
8/10/2017HC WainwrightSet Price TargetBuy$11.00High
7/11/2017HC WainwrightSet Price TargetBuy$11.00High
7/11/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$11.00Low
7/4/2017FBR & Co.Reiterated RatingBuyMedium
5/12/2017FBR & Co.Reiterated RatingBuy$11.00Low
4/6/2017FBR & Co.Reiterated RatingBuyLow
3/22/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$11.00Medium
11/18/2016FBR & Co.Reiterated RatingBuyN/A
10/3/2016Roth CapitalInitiated CoverageBuy$9.00N/A
(Data available from 9/24/2016 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/25/2021
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/24/2021

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Fortress Biotech logo
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the following Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded on June 28, 2006 and is headquartered in New York, NY.
Read More

Today's Range

Now: $3.44
Low: $3.32
High: $3.44

50 Day Range

MA: $3.20
Low: $2.82
High: $3.46

52 Week Range

Now: $3.44
Low: $2.12
High: $6.10

Volume

232,107 shs

Average Volume

1,016,265 shs

Market Capitalization

$347.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Fortress Biotech?

The following Wall Street sell-side analysts have issued research reports on Fortress Biotech in the last twelve months: B. Riley, Benchmark Co., Cantor Fitzgerald, Dawson James, HC Wainwright, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for FBIO.

What is the current price target for Fortress Biotech?

5 Wall Street analysts have set twelve-month price targets for Fortress Biotech in the last year. Their average twelve-month price target is $10.60, suggesting a possible upside of 208.1%. Dawson James has the highest price target set, predicting FBIO will reach $21.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $5.00 for Fortress Biotech in the next year.
View the latest price targets for FBIO.

What is the current consensus analyst rating for Fortress Biotech?

Fortress Biotech currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FBIO will outperform the market and that investors should add to their positions of Fortress Biotech.
View the latest ratings for FBIO.

What other companies compete with Fortress Biotech?

How do I contact Fortress Biotech's investor relations team?

Fortress Biotech's physical mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company's listed phone number is (781) 652-4500 and its investor relations email address is [email protected] The official website for Fortress Biotech is www.fortressbiotech.com.